Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
01 March 2024 | Story Leonie Bolleurs | Photo SUPPLIED
Dr Lucas Erasmus
Dr Lucas Erasmus, Junior Researcher in the Department of Physics, has just returned from Belgium where he had his public defence of a joint PhD with Ghent University, titled: Luminescent solar concentrators – where Sm2+ doped phosphors shine.

“I like taking what I have learned from literature and going to the laboratory to test it. Sometimes the results surprise me, leading to additional experiments or refining. This process could continue for several months and even years, with me slowly building the puzzle. And finally, one day, all the pieces come together, and everything becomes very clear to me as a physicist. And if I am lucky, I will have the privilege of knowing a secret about nature that nobody else has known up to this point. However, as an innovator, I am tasked with using this new knowledge to develop ways to manipulate nature to deliver a helpful device.”

These are the thoughts of Dr Lucas Erasmus, Junior Researcher in the Department of Physics at the University of the Free State (UFS), who has just returned from Ghent, Belgium, where he had his public defence of a joint PhD with Ghent University, titled: Luminescent solar concentrators – where Sm2+ doped phosphors shine.

The research project is part of a bilateral collaboration between the Department of Physics at the UFS and the Department of Solid State Sciences at Ghent University. In this study, the strengths, experience, and resources of both research groups – experienced in developing luminescent materials for various applications – are used to ensure a stronger final product. To meet the requirements stipulated in the cooperation agreement between the two institutions for the joint supervision and certification of Dr Erasmus’ doctoral studies, research was conducted both at the UFS and at Ghent University.

Dr Erasmus’ research is significant in the light of rising energy prices, energy scarcity, and the pursuit of a carbon-free society, where there are strong incentives to develop new and renewable energy sources.

Combining windows and solar cells increase their relevancy in many applications

He says that although solar panels play an essential role in renewable energy – since they provide a route to directly convert solar radiation into electricity – there are limitations to installing conventional panels, which are bulky, rigid, and opaque. He believes that combining windows and solar cells could increase their relevance in the built environment, agricultural sector, and modern consumer electronics.

Explaining about the luminescent solar concentrator (LSC) in his study, he states that it is a device used as a large-area solar radiation collector that converts and emits radiation. The emitted radiation is directed to photovoltaic cells located in the small side area of the device. According to him, a basic LSC consists of a transparent waveguide with an embedded luminescent material and a strategically placed photovoltaic cell on the edge.

Dr Erasmus continues, “The large area of the waveguide collects a portion of the solar radiation, while the luminescent material absorbs the energy and downshifts it to longer wavelengths. Internal reflection directs the emitted photons towards smaller areas on the sides where the photovoltaic cells are used to convert the concentrated light into electricity.”

In his view, creating a large and efficient LSC is a challenging endeavour that requires an in-depth study of multiple domains. “This includes developing and optimising the luminescent material, studying its behaviour and the characteristics of the waveguide, and finally adding these two components and developing, characterising, and simulating the hybrid device,” he remarks.

“While the current prototype we have developed delivers good results, it is still far from perfect and not commercially viable,” he says, stating that this study could, however, serve as a guide for future researchers interested in developing LCSs. Dr Erasmus believes the underlying science behind the results contributes to a general understanding of the materials, making this study valuable to other fields and contributing to the larger body of science. At the end of the study, he also makes some recommendations for future research in this field. 

Study a reflection of theoretical knowledge and a practical system

The public defence consisted of both an internal and an external defence. The internal defence took place in January at the UFS between Dr Erasmus and the examination committee. The external defence occurred at Ghent University and was also open to the broader public. Also present at this event in Belgium were colleagues from the UFS – Prof David Motaung, an examiner; Prof Koos Terblans, co-supervisor; and Prof Hendrik Swart, supervisor for the PhD thesis.

Dr Erasmus’ experience of the oral examination was that the examiners were primarily positive in their critique but also thorough in their questioning. According to him, some of their remarks pointed out that they were impressed with the meticulous planning, execution, and interpretation of the experimental results and that the researchers involved ensured that any parameter that might have influenced the device was maximised. “Moreover, they liked the fact that I went all the way from theoretical knowledge to a practical system. The examiners also noted that the study compares well with the current state-of-the-art research in the field,” adds Dr Erasmus.

He says that having the public defence in Belgium was a once-in-a-lifetime experience, allowing him to interact and deliberate directly with the examiners and communicate their findings and conclusions to the broader public. Dr Erasmus hopes that this will lead to stronger collaboration and better public sentiment toward spending funding for scientific projects.

For future steps, he states, the research group involved in the project plans to continue this research by further increasing the device's efficiency. “To this end, we have already developed another luminescent material that can address some of the challenges we encountered while developing the first prototype device. This forms part of the work that Johané Odendaal is doing in her master’s degree, of which I am a co-supervisor. We also plan to enlarge the scope of our research to consider the challenges that are currently hampering the next generation of photovoltaic cells and to find ways in which we could address these issues,” comments Dr Erasmus.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept